Trial Profile
A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Paclitaxel (Primary) ; Carboplatin; Gemcitabine
- Indications Adenocarcinoma; Advanced breast cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb; Celgene Corporation
- 18 Jun 2020 Results from advanced pancreatic cancer cohort published in the Clinical Cancer Research
- 19 Jan 2019 Results assesing nivolumab + nab-paclitaxel + gemcitabine in advanced pancreatic cancer (n=50) presented at the 2019 Gastrointestinal Cancers Symposium
- 25 Oct 2018 Status changed from active, no longer recruiting to completed.